Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Core Viewpoint - Invivyd, Inc. has initiated a discovery program for a measles monoclonal antibody (mAb) in response to inquiries from healthcare providers, as there are currently no approved therapies for measles or post-exposure prophylaxis [1][6] Company Overview - Invivyd, Inc. is a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, utilizing a proprietary integrated technology platform for developing best-in-class antibodies [7] Industry Context - There are no antiviral treatments for measles, with current options being limited to high-dose Vitamin A and human donor-derived pooled plasma immune globulin (IVIG), both of which have significant limitations [2] - Standard measles vaccines are effective but face challenges in post-exposure prophylaxis and are underutilized due to access issues and personal beliefs [3] - The resurgence of measles outbreaks globally, including in the U.S., poses a significant public health risk, with over 20 million unvaccinated Americans [5][6] Health Implications - Acute measles infection can lead to severe complications, including hospitalization in one in four cases and death in one in every 1,000 cases [4] - The decline in vaccination rates has serious health consequences, potentially leading to the reestablishment of previously eradicated pathogens like measles [3][5] Development Goals - Invivyd aims to identify a preclinical measles mAb candidate by 2025 and plans to provide updates on progress by the end of the year [6] - The company is focused on developing a safe, convenient, and highly effective mAb against measles that can be easily integrated into clinical practice [7]